Art. -Nr.: HY-90009A

Copy Link Print Information

Tadalafil

(Synonyms: IC-351)

9 Cited Publications

Kundenbewertung

Based on 9 publication(s) in Google Scholar

Tadalafil (IC-351) is a PDE5 inhibitor with an IC₅₀ value of 1.8 nM.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.95%
CAS. Nr.: 171596-29-5
Formel: C₂₂H₁₉N₃O₄
Molecular Weight:389.40

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months

Tadalafil Chemical Structure

CAS. Nr.: 171596-29-5

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (9)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Tadalafil (IC-351) is a PDE5 inhibitor with an IC₅₀ value of 1.8 nM.

IC₅₀ & Target

PDE5

Alle Phosphodiesterase (PDE) Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	105.5 μM Compound: Tadalafil	Antiproliferative activity against human A549 cells measured after 48 hrs by MTT assay Antiproliferative activity against human A549 cells measured after 48 hrs by MTT assay	[PMID: 39149110]
A549	IC₅₀	12.2 μM Compound: Tadalafil	Potentiation of cisplatin-induced cytotoxicity against human A549 cells assessed as cisplatin IC50 at 1:4 ratio of cisplatin to compound measured after 48 hrs by MTT assay Potentiation of cisplatin-induced cytotoxicity against human A549 cells assessed as cisplatin IC50 at 1:4 ratio of cisplatin to compound measured after 48 hrs by MTT assay	[PMID: 39149110]
A549	IC₅₀	23.5 μM Compound: Tadalafil	Potentiation of raloxifene-induced cytotoxicity against human A549 cells assessed as raloxifene IC50 at 1:2 ratio of raloxifene to compound measured after 48 hrs by MTT assay Potentiation of raloxifene-induced cytotoxicity against human A549 cells assessed as raloxifene IC50 at 1:2 ratio of raloxifene to compound measured after 48 hrs by MTT assay	[PMID: 39149110]
A549	IC₅₀	353.7 μM Compound: Tadalafil	Antiproliferative activity against human A549 cells measured after 24 hrs by MTT assay Antiproliferative activity against human A549 cells measured after 24 hrs by MTT assay	[PMID: 39149110]
A549	IC₅₀	73.9 μM Compound: Tadalafil	Antiproliferative activity against human A549 cells measured after 72 hrs by MTT assay Antiproliferative activity against human A549 cells measured after 72 hrs by MTT assay	[PMID: 39149110]
HT-29	IC₅₀	>100 μM Compound: Tadalafil	Growth inhibition of human HT-29 cells after 72 hrs by cell titer glo assay Growth inhibition of human HT-29 cells after 72 hrs by cell titer glo assay	[PMID: 20206015]
MRC5	IC₅₀	>64 μM Compound: 1	Cytotoxicity against human MRC5 SV2 cells after 72 hrs Cytotoxicity against human MRC5 SV2 cells after 72 hrs	[PMID: 21504142]
MRC5	CC₅₀	>64 μM Compound: 1	Cytotoxicity against human MRC5 SV2 cells after 72 hrs using resazurin by fluorimetry Cytotoxicity against human MRC5 SV2 cells after 72 hrs using resazurin by fluorimetry	[PMID: 22204607]
NCI-H1299	IC₅₀	127.3 μM Compound: Tadalafil	Antiproliferative activity against human NCI-H1299 cells measured after 72 hrs by MTT assay Antiproliferative activity against human NCI-H1299 cells measured after 72 hrs by MTT assay	[PMID: 39149110]
NCI-H1299	IC₅₀	274 μM Compound: Tadalafil	Antiproliferative activity against human NCI-H1299 cells measured after 48 hrs by MTT assay Antiproliferative activity against human NCI-H1299 cells measured after 48 hrs by MTT assay	[PMID: 39149110]
NCI-H1299	IC₅₀	358.8 μM Compound: Tadalafil	Antiproliferative activity against human NCI-H1299 cells measured after 24 hrs by MTT assay Antiproliferative activity against human NCI-H1299 cells measured after 24 hrs by MTT assay	[PMID: 39149110]
NCI-H1299	IC₅₀	7.8 μM Compound: Tadalafil	Potentiation of cisplatin-induced cytotoxicity against human NCI-H1299 cells assessed as cisplatin IC50 at 1:35 ratio of cisplatin to compound measured after 48 hrs by MTT assay Potentiation of cisplatin-induced cytotoxicity against human NCI-H1299 cells assessed as cisplatin IC50 at 1:35 ratio of cisplatin to compound measured after 48 hrs by MTT assay	[PMID: 39149110]
NCI-H1299	IC₅₀	8.6 μM Compound: Tadalafil	Potentiation of raloxifene-induced cytotoxicity against human NCI-H1299 cells assessed as raloxifene IC50 at 1:20 ratio of raloxifene to compound measured after 48 hrs by MTT assay Potentiation of raloxifene-induced cytotoxicity against human NCI-H1299 cells assessed as raloxifene IC50 at 1:20 ratio of raloxifene to compound measured after 48 hrs by MTT assay	[PMID: 39149110]
NCI-H661	IC₅₀	21 μM Compound: Tadalafil	Potentiation of raloxifene-induced cytotoxicity against human NCI-H661 cells assessed as raloxifene IC50 at 1:7 ratio of raloxifene to compound measured after 48 hrs by MTT assay Potentiation of raloxifene-induced cytotoxicity against human NCI-H661 cells assessed as raloxifene IC50 at 1:7 ratio of raloxifene to compound measured after 48 hrs by MTT assay	[PMID: 39149110]
NCI-H661	IC₅₀	242.8 μM Compound: Tadalafil	Antiproliferative activity against human NCI-H661 cells measured after 72 hrs by MTT assay Antiproliferative activity against human NCI-H661 cells measured after 72 hrs by MTT assay	[PMID: 39149110]
NCI-H661	IC₅₀	280.9 μM Compound: Tadalafil	Antiproliferative activity against human NCI-H661 cells measured after 48 hrs by MTT assay Antiproliferative activity against human NCI-H661 cells measured after 48 hrs by MTT assay	[PMID: 39149110]
NCI-H661	IC₅₀	875.7 μM Compound: Tadalafil	Antiproliferative activity against human NCI-H661 cells measured after 24 hrs by MTT assay Antiproliferative activity against human NCI-H661 cells measured after 24 hrs by MTT assay	[PMID: 39149110]
NCI-H661	IC₅₀	9.9 μM Compound: Tadalafil	Potentiation of cisplatin-induced cytotoxicity against human NCI-H661 cells assessed as cisplatin IC50 at 1:14 ratio of cisplatin to compound measured after 48 hrs by MTT assay Potentiation of cisplatin-induced cytotoxicity against human NCI-H661 cells assessed as cisplatin IC50 at 1:14 ratio of cisplatin to compound measured after 48 hrs by MTT assay	[PMID: 39149110]
Sf9	IC₅₀	37 nM Compound: 2	Inhibitory activity against phosphodiesterase 11 (PDE11) obtained from recombinant Sf9 expression Inhibitory activity against phosphodiesterase 11 (PDE11) obtained from recombinant Sf9 expression	[PMID: 12668004]
Sf9	IC₅₀	>10000 nM Compound: Tadalafil	Inhibition of human PDE2A1 expressed in baculovirus infected sf9 cells using [3H]cAMP as substrate measured after 30 mins by scintillation proximity assay Inhibition of human PDE2A1 expressed in baculovirus infected sf9 cells using [3H]cAMP as substrate measured after 30 mins by scintillation proximity assay	[PMID: 31021628]
Sf9	IC₅₀	>10000 nM Compound: Tadalafil	Inhibition of N-terminal GST-tagged full length human PDE9A2 expressed in baculovirus infected sf9 cells using [3H]cGMP as substrate measured after 30 mins by scintillation proximity assay Inhibition of N-terminal GST-tagged full length human PDE9A2 expressed in baculovirus infected sf9 cells using [3H]cGMP as substrate measured after 30 mins by scintillation proximity assay	[PMID: 31021628]
Sf9	IC₅₀	>10000 nM Compound: Tadalafil	Inhibition of N-terminal GST-tagged human PDE1 expressed in baculovirus infected sf9 cells using [3H]cAMP as substrate measured after 30 mins by scintillation proximity assay Inhibition of N-terminal GST-tagged human PDE1 expressed in baculovirus infected sf9 cells using [3H]cAMP as substrate measured after 30 mins by scintillation proximity assay	[PMID: 31021628]
Sf9	IC₅₀	>10000 nM Compound: Tadalafil	Inhibition of N-terminal GST-tagged human PDE10A expressed in baculovirus infected sf9 cells using [3H]cAMP as substrate measured after 30 mins by scintillation proximity assay Inhibition of N-terminal GST-tagged human PDE10A expressed in baculovirus infected sf9 cells using [3H]cAMP as substrate measured after 30 mins by scintillation proximity assay	[PMID: 31021628]
Sf9	IC₅₀	>10000 nM Compound: Tadalafil	Inhibition of N-terminal GST-tagged human PDE3 expressed in baculovirus infected sf9 cells using [3H]cAMP as substrate measured after 30 mins by scintillation proximity assay Inhibition of N-terminal GST-tagged human PDE3 expressed in baculovirus infected sf9 cells using [3H]cAMP as substrate measured after 30 mins by scintillation proximity assay	[PMID: 31021628]
Sf9	IC₅₀	>10000 nM Compound: Tadalafil	Inhibition of N-terminal GST-tagged human PDE4 expressed in baculovirus infected sf9 cells using [3H]cAMP as substrate measured after 30 mins by scintillation proximity assay Inhibition of N-terminal GST-tagged human PDE4 expressed in baculovirus infected sf9 cells using [3H]cAMP as substrate measured after 30 mins by scintillation proximity assay	[PMID: 31021628]
Sf9	IC₅₀	>10000 nM Compound: Tadalafil	Inhibition of N-terminal GST-tagged human PDE7 expressed in baculovirus infected sf9 cells using [3H]cAMP as substrate measured after 30 mins by scintillation proximity assay Inhibition of N-terminal GST-tagged human PDE7 expressed in baculovirus infected sf9 cells using [3H]cAMP as substrate measured after 30 mins by scintillation proximity assay	[PMID: 31021628]
Sf9	IC₅₀	2.35 nM Compound: Tadalafil	Inhibition of N-terminal GST-tagged human PDE5A1 expressed in baculovirus infected sf9 cells using [3H]cGMP as substrate measured after 30 mins by scintillation proximity assay Inhibition of N-terminal GST-tagged human PDE5A1 expressed in baculovirus infected sf9 cells using [3H]cGMP as substrate measured after 30 mins by scintillation proximity assay	[PMID: 31021628]
Sf9	IC₅₀	22.1 nM Compound: Tadalafil	Inhibition of N-terminal GST-tagged human PDE11A4 expressed in baculovirus infected sf9 cells using [3H]cGMP as substrate measured after 30 mins by scintillation proximity assay Inhibition of N-terminal GST-tagged human PDE11A4 expressed in baculovirus infected sf9 cells using [3H]cGMP as substrate measured after 30 mins by scintillation proximity assay	[PMID: 31021628]
Sf9	IC₅₀	402 nM Compound: Tadalafil	Inhibition of N-terminal GST-tagged human PDE6C expressed in baculovirus infected sf9 cells using [3H]cGMP as substrate measured after 30 mins by scintillation proximity assay Inhibition of N-terminal GST-tagged human PDE6C expressed in baculovirus infected sf9 cells using [3H]cGMP as substrate measured after 30 mins by scintillation proximity assay	[PMID: 31021628]
Sf9	IC₅₀	>10000 nM Compound: Tadalafil	Inhibition of N-terminal GST-tagged full length human PDE8A1 expressed in baculovirus infected sf9 cells using [3H]cAMP as substrate measured after 30 mins by scintillation proximity assay Inhibition of N-terminal GST-tagged full length human PDE8A1 expressed in baculovirus infected sf9 cells using [3H]cAMP as substrate measured after 30 mins by scintillation proximity assay	[PMID: 31021628]

In Vitro

Biochemical potencies (affinities) of these compounds for PDE5 determined by IC(50), K(D) (isotherm), K(D) (dissociation rate), and K(D) ((1/2) EC(50)), respectively, were the following: sildenafil (3.7 +/- 1.4, 4.8 +/- 0.80, 3.7 +/- 0.29, and 11.7 +/- 0.70 nM), tadalafil (1.8 +/- 0.40, 2.4 +/- 0.60, 1.9 +/- 0.37, and 2.7 +/- 0.25 nM); and vardenafil (0.091 +/- 0.031, 0.38 +/- 0.07, 0.27 +/- 0.01, and 0.42 +/- 0.10 nM). Thus, absolute potency values were similar for each inhibitor, and relative potencies were vardenafil >> tadalafil > sildenafil^[1].
0.5 ml tadalafil solutions with different concentrations were added (0.2, 0.1, 0.05 and 0.025 μg ml-1, respectively) into semen samples. In both groups, samples treated with 0.2 μg ml-1 tadalafil had significant increase in sperm motility after 2 h incubation^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

The Tadalafil-treated group showed enhanced erectile function (intracavernosal pressure/mean arterial pressure) at 0.3, 0.5, 1, 3, and 5 Hz compared with diabetic group values at the respective frequencies that approached control values^[3].
Oral administration of tadalafil (20 mg) or sildenafil (100 mg) was given. In both groups, computer-assisted semen analysis parameters showed no significant difference. After the administration of tadalafil (2 h) and sildenafil (1 h), there was no significant difference observed in premature acrosome reaction incidence rate^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 171596-29-5
Appearance Solid
Molecular Weight 389.40
Formel C₂₂H₁₉N₃O₄
Color White to off-white
SMILES

O=C([C@@]1([H])CC2=C([C@@H](C3=CC=C(OCO4)C4=C3)N15)NC6=C2C=CC=C6)N(C)CC5=O
Synonyms

IC-351
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (9)

All Cell Proliferation/Viability AssayRT-PCRIn Vivo Efficacy StudyWBIHC

Sort by:

Journal Impact Factor

Transl Psychiatry

Exploring PDE5A upregulation in bipolar disorder: insights from single-nucleus RNA sequencing of human basal ganglia. [Abstract]

2024 Dec 18;14(1):494. PMID: 39695100
Cancer Metab

Tadalafil increases the antitumor activity of 5-FU through inhibiting PRMT5-mediated glycolysis and cell proliferation in colorectal cancer. [Abstract]

2022 Dec 6;10(1):22. PMID: 36474242

Tadalafil purchased from MedChemExpress. Usage Cited in: Cancer Metab. 2022 Dec 6;10(1):22. [Abstract]

Tadalafil (TAD; 10, 20, 50 µM) for 24 h was evaluated by MTT assay.

Tadalafil purchased from MedChemExpress. Usage Cited in: Cancer Metab. 2022 Dec 6;10(1):22. [Abstract]

Fold change relative to control of glycolytic enzymes in HCT116 cells treated with or without Tadalafil (TAD; 25 µM) for 24 h.

Tadalafil purchased from MedChemExpress. Usage Cited in: Cancer Metab. 2022 Dec 6;10(1):22. [Abstract]

Tumor volume and mass of nude mice were remarkably reduced after administrated with Tadalafil (2 mg/kg, p.o.) and 5-FU combination.

Tadalafil purchased from MedChemExpress. Usage Cited in: Cancer Metab. 2022 Dec 6;10(1):22. [Abstract]

Western blotting analysis to assess LDHA levels in tumor samples treated with 5-FU and Tadalafil (2 mg/kg, p.o.) (TAD).

Tadalafil purchased from MedChemExpress. Usage Cited in: Cancer Metab. 2022 Dec 6;10(1):22. [Abstract]

IHC staining showed that the expression of LDHA was significantly declined in combination of Tadalafil (2 mg/kg, p.o.) with 5-FU.
Int J Mol Sci

Novel Chemicals Derived from Tadalafil Exhibit PRMT5 Inhibition and Promising Activities against Breast Cancer. [Abstract]

2022 Apr 27;23(9):4806. PMID: 35563196
Biol Direct

Phosphodiesterase type 5 inhibitor tadalafil reduces prostatic fibrosis via MiR-3126-3p/FGF9 axis in benign prostatic hyperplasia. [Abstract]

2024 Aug 2;19(1):61. PMID: 39095835
Analyst

Evaluation of vardenafil's metabolic stability in human liver microsomes through ultra-fast UPLC-MS/MS for quantitative analysis, including assessments of greenness, ADME properties, DEREK alerts, and metabolic lability. [Abstract]

2026 Jun 15;151(12):3550-3561. PMID: 42132584
Biochem Biophys Res Commun

Lactic acid inhibits iNKT cell functions via a phosphodiesterase-5 dependent pathway. [Abstract]

2021 Apr 2:547:9-14. PMID: 33588236
Biomed Pharmacother

Drug repositioning: Identification of potent inhibitors of NS3 protease and NS5 RdRp for control of DENV infection. [Abstract]

2025 Jun:187:118104. PMID: 40300391
bioRxiv

Exploring Integrin α5β1 as a Potential Therapeutic Target for Pulmonary Arterial Hypertension: Insights from Comprehensive Multicenter Preclinical Studies. [Abstract]

2024 Jun 1:2024.05.27.596052. PMID: 38854025
Patent

US20210052581A1.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : ≥ 52 mg/mL (133.54 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.5681 mL

12.8403 mL

25.6805 mL

5 mM

0.5136 mL

2.5681 mL

5.1361 mL

10 mM

0.2568 mL

1.2840 mL

2.5681 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (6.42 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (284 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Blount MA, et al. Binding of tritiated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency,specificity, heterogeneity, and cGMP stimulation. Mol Pharmacol. 2004 Jul;66(1):144-52. [Content Brief]

[2]. Yang Y, et al. Effect of acute tadalafil on sperm motility and acrosome reaction: in vitro and in vivo studies. Andrologia. 2013 Apr 14. [Epub ahead of print] [Content Brief]

[3]. Mostafa ME, et al. Effect of Chronic Low-dose Tadalafil on Penile Cavernous Tissues in Diabetic Rats. Urology. 2013 Jun;81(6):1253-60. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.5681 mL	12.8403 mL	25.6805 mL	64.2013 mL
	5 mM	0.5136 mL	2.5681 mL	5.1361 mL	12.8403 mL
	10 mM	0.2568 mL	1.2840 mL	2.5681 mL	6.4201 mL
	15 mM	0.1712 mL	0.8560 mL	1.7120 mL	4.2801 mL
	20 mM	0.1284 mL	0.6420 mL	1.2840 mL	3.2101 mL
	25 mM	0.1027 mL	0.5136 mL	1.0272 mL	2.5681 mL
	30 mM	0.0856 mL	0.4280 mL	0.8560 mL	2.1400 mL
	40 mM	0.0642 mL	0.3210 mL	0.6420 mL	1.6050 mL
	50 mM	0.0514 mL	0.2568 mL	0.5136 mL	1.2840 mL
	60 mM	0.0428 mL	0.2140 mL	0.4280 mL	1.0700 mL
	80 mM	0.0321 mL	0.1605 mL	0.3210 mL	0.8025 mL
	100 mM	0.0257 mL	0.1284 mL	0.2568 mL	0.6420 mL

Keywords

Tadalafil

9 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Tadalafil

Anti-diabetic Compound Library

Anti-Cardiovascular Disease Compound Library

Endocrinology Compound Library

NMPA-Approved Drug Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Alzheimer's Disease Compound Library

Drug-Induced Liver Injury (DILI) Compound Library

Anti-Pancreatic Cancer Compound Library

Neurodegenerative Disease-related Compound Library

Rare Diseases Drug Library

Anti-Colorectal Cancer Compound Library

Pediatric Drug Library

EMA-Approved Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Non-steroidal Anti-Inflammatory Compound Library

Off-patent Drug Library

Metabolic Enzyme Compound Library

Cell Death Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Chinese Baijiu Compound Library

Classic FDA-Approved Drug Library

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Drug Repurposing Compound Library

Publications Citing Use of MedChemExpress (MCE) Tadalafil

Alle Phosphodiesterase (PDE) Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (9)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Tadalafil Related Classifications

HY-90009A Related Classifications